Synapse - Interim results of a phase II trial of first line retifanlimab (R) plus gemcitabine and docetaxel (GD) in patients (pts) with advanced soft tissue sarcoma (STS)

Interim results of a phase II trial of first line retifanlimab (R) plus gemcitabine and docetaxel (GD) in patients (pts) with advanced soft tissue sarcoma (STS) Meeting Abstract

Authors:	Rosenbaum, E.; Qin, L. X.; Dickson, M. A.; Keohan, M. L.; Gounder, M. M.; Chi, P.; Movva, S.; Kelly, C. M.; Avutu, V.; Chan, J. E.; Martindale, M.; Adamson, T.; Clark, C.; Desir, R.; Biniakewitz, M.; Cho, G.; Erinjeri, J. P.; Lefkowitz, R. A.; Tap, W. D.; D'Angelo, S. P.
Abstract Title:	Interim results of a phase II trial of first line retifanlimab (R) plus gemcitabine and docetaxel (GD) in patients (pts) with advanced soft tissue sarcoma (STS)
Meeting Title:	2023 ASCO Annual Meeting
Journal Title:	Journal of Clinical Oncology
Volume:	41
Issue:	16 Suppl.
Meeting Dates:	2023 Jun 2-6
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2023-06-01
Language:	English
DOI:	10.1200/JCO.2023.41.16_suppl.11518
PROVIDER:	EBSCOhost
PROVIDER:	cinahl
DOI/URL:	https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,shib&db=cin20&AN=164013120&authtype=sso&custid=s2915669&site=ehost-live&scope=site&custid=s2915669
Notes:	Meeting abstract: 11518 -- Meeting also presented virtually -- Source: Cinahl